Experimental Drug for Alzheimer Disease Shows Promise
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques.
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques.
The investigational treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
Overall, Rx filled for antidepressants in 49.8 percent, opioids in 29.8 percent, anxiolytics in 26.8 percent
This week we have remdesivir news; A new opioid and spinal muscular atrophy treatments are approved; A sublingual epinephrine treatment; And the latest on Biogen’s investigational Alzheimer disease treatment. Also, we have a brief summary of the other drugs in the pipeline from the past week.
The FDA has accepted for Priority Review the Biologics License Application for aducanumab (Biogen) for the treatment of Alzheimer disease.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Biogen has submitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for aducanumab as a treatment of Alzheimer disease (AD).
Tauvid is indicated for use with positron emission tomography (PET) imaging of the brain.
Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
Risk increases associated with hormone therapy exposure over 10 years in women <60 years at initiation